UCB (OTCMKTS:UCBJY) Shares Gap Down – Here’s Why

UCB SA (OTCMKTS:UCBJY) gapped down prior to trading on Monday . The stock had previously closed at $151.41, but opened at $144.48. UCB shares last traded at $144.87, with a volume of 1,975 shares trading hands.

Wall Street Analysts Forecast Growth

UCBJY has been the subject of a number of research reports. Zacks Research raised shares of UCB from a “strong sell” rating to a “hold” rating in a report on Monday. Barclays lowered shares of UCB from a “strong-buy” rating to a “hold” rating in a research report on Monday, June 15th. Finally, Jefferies Financial Group upgraded shares of UCB to a “moderate sell” rating in a report on Monday, June 22nd. Two research analysts have rated the stock with a Strong Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy”.

UCB Stock Performance

The firm’s 50-day moving average price is $143.65 and its two-hundred day moving average price is $148.03. The company has a current ratio of 1.38, a quick ratio of 1.04 and a debt-to-equity ratio of 0.20.

About UCB

UCB is a global biopharmaceutical company founded in Belgium in 1928, specializing in the discovery and development of therapies for severe diseases in the fields of neurology and immunology. Headquartered in Brussels, UCB leverages nearly a century of scientific expertise to address areas of high unmet medical need, with a focus on chronic conditions such as epilepsy, Parkinson’s disease, rheumatoid arthritis and Crohn’s disease.

The company’s commercial portfolio includes key branded medicines such as CIMZIA (certolizumab pegol) for inflammatory disorders, VIMPAT (lacosamide) for the treatment of partial-onset seizures in epilepsy, and NEUPRO (rotigotine transdermal system) for Parkinson’s disease and restless legs syndrome.